Aseptika

NHS Problem

In the UK, 1.1 million children and young people are affected by asthma, with the country experiencing the highest rates of hospital admissions for asthma attacks in Europe. Asthma attacks disproportionately impact children and young individuals residing in areas of significant deprivation and those from marginalised groups, exacerbating existing health inequities.

The Solution

PUFFClicker3 is a universal smart inhaler tracker designed to enhance adherence across all age groups. Compatible with both dry powder and metered dose inhalers (101 SNOMED coded inhalers supported), its interactive touchscreen displays in 16 languages, ensuring accessibility for all users. PUFFClicker3 seamlessly transmits data to and from the Aseptika Cloud via the mobile network, eliminating the need for a smartphone. 

Official launch: June 5th, 2024, at the MedTech Innovations Expo held at the NEC. 

Certified as a UKCA and CE (EU MDR 2017/745) Class I medical device, PUFFClicker3 is registered with the MHRA, ensuring compliance with regulatory standards. 

Impact

PUFFClicker3 will be deployed as a screening intervention within community care settings to evaluate the adherence of children and young individuals to their asthma care plans. This brief intervention will span just 30 days and may serve as an interim measure before potential referral to an asthma specialist in secondary care and will be targeted at the Core20PLUS patient groups. 

Currently, waiting times for an initial review by an asthma specialist in secondary care vary from 11 to 24 weeks, with some cases extending up to 56 weeks, far exceeding the recommended maximum of 18 weeks. To address this issue, the effectiveness of this new intervention will be assessed in two clinical centres, supported by SBRI Healthcare23.